New York, NY -- (SBWIRE) -- 01/13/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Mast Therapeutics Inc (NYSEMKT:MSTX), ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC), Antares Pharma Inc (NASDAQ:ATRS), ZIOPHARM Oncology Inc (NASDAQ:ZIOP)
Mast Therapeutics Inc (NYSEMKT:MSTX) showed a volume of 2.69 million shares by the end of last trade whereas the average volume of the stock remained 2.01 million shares. The stock opened the session at $0.54 but then moved to $0.530. At that price, the stock showed a negative performance of -2.75%. Mast Therapeutics, Inc., formerly ADVENTRX Pharmaceuticals, Inc., is a development-stage company biopharmaceutical company focused on developing product candidates. The Company's product candidate is ANX-188, a rheologic, antithrombotic and cytoprotective agent that improves microvascular blood flow and has application in treating a range of diseases and conditions, such as complications arising from sickle cell disease. As of December 31, 2011, the Company also is developing ANX-514, a detergent-free formulation of the chemotherapy drug docetaxel.
Will MSTX Get Buyers Even After The Recent Rally? Find Out Here
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) opened the session at $0.99 and closed the session at $0.989. The stock showed a positive performance of 7.61% in previous trading session. Traded with volume of 2.69 million shares in the prior session and the average volume of the stock remained 3.85 million shares. ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors. Immunotherapy is an approach to treat cancer in which a patient’s own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies.
For How Long IMUC will fight for Profitability? Read This Trend Analysis report
Antares Pharma Inc (NASDAQ:ATRS) opened the session at $4.93 and closed the session at $4.95. The stock showed a positive performance of 1.43% in previous trading session. Traded with volume of 2.67 million shares in the prior session and the average volume of the stock remained 1.35 million shares. The beta of the stock remained 0.14. Antares Pharma, Inc. (Antares) is a pharma company that focuses on self-injection pharmaceutical products and technologies and topical gel-based products. The Company’s subcutaneous and intramuscular injection technology platforms include Vibex disposable pressure-assisted auto injectors, Vision reusable needle-free injectors, and disposable multi-use pen injectors. In the injector area, it has licensed its reusable needle-free injection device for use with human growth hormone (hGH) to Teva, Ferring Pharmaceuticals BV (Ferring) and JCR Pharmaceuticals Co., Ltd. (JCR), with Teva and Ferring being its two primary customers.
Why Should Investors Buy ATRS After The Recent Gain? Just Go Here and Find Out
ZIOPHARM Oncology Inc (NASDAQ:ZIOP) the stock advanced 11.27% and finished the session at $4.74. Traded with volume of 2.66 million shares in the prior session and the average volume of the stock remained 1.23 million shares. The beta of the stock remained 1.58. ZIOPHARM Oncology, Inc., is a biotechnology company. The Company employs gene expression and control technology to deliver deoxyribonucleic acid (DNA) for the treatment of cancer. The Company's technology employs Intrexon Corporation's RheoSwitch Therapeutic System to turn on and off, and precisely modulate, gene expression at the cancer site in order to improve the therapeutic index.
Will ZIOP Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)